Treatment of Papillary Thyroid Carcinoma With Radiofrequency Ablation (NCT04129411) | Clinical Trial Compass
CompletedNot Applicable
Treatment of Papillary Thyroid Carcinoma With Radiofrequency Ablation
United States5 participantsStarted 2020-06-15
Plain-language summary
Investigators intend to evaluate the efficiency of Radiofrequency ablation (RFA) therapy to treat papillary thyroid carcinoma.
Who can participate
Age range18 Years – 85 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Are adults
* Nodule with Papillary thyroid carcinoma meeting the below criteria:
* Diagnosed by fine needle aspiration (FNA) cytology.
* Size \< 1.5 cm
* Non-surgical therapy is considered acceptable by the treating physician
* Radiology evaluation deems the lesion amenable to RFA therapy with minimal risk of complication
Exclusion Criteria:
* Clinical evidence for a multifocal papillary thyroid malignancy
* Clinical evidence for local or distant metastatic disease
* Pregnancy
* Vocal cord paralysis on contralateral side
* Coagulopathy or patients on anticoagulation therapy
* Patients with prior neck surgery or neck radiation
* Patients with neck anatomy that precludes easy access by RFA
* Patients with comorbidities deemed too high of a risk for general anesthesia
* Treatment with another investigational drug or intervention (within 6 weeks of planned RFA).
* Current drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements.